西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2014年
6期
601-604
,共4页
瑞舒伐他汀%辛伐他汀%慢性心力衰竭%疗效
瑞舒伐他汀%辛伐他汀%慢性心力衰竭%療效
서서벌타정%신벌타정%만성심력쇠갈%료효
rosuvastatin%simvastatin%chronic heart failure(CHF)%curative effect
目的:比较瑞舒伐他汀和辛伐他汀对慢性心力衰竭( CHF)的疗效。方法选取CHF患者108例,随机分为两组,在常规治疗的基础上,分别加用辛伐他汀(20 mg/d)和瑞舒伐他汀(20 mg/d)治疗,疗程为6个月。在治疗前后,检测患者低密度脂蛋白胆固醇( LDL-C)、高密度脂蛋白胆固醇( HDL-C)、高敏C反应蛋白( hs-CRP)、B型尿钠肽( BNP)、左室射血分数( LVEF)、左室舒张末内径( LVEDD),并评估纽约心脏病学会( NYHA)心功能分级,记录6 min步行距离。结果瑞舒伐他汀组和辛伐他汀组总有效率分别为90.74%、75.93%,有统计学差异( P﹤0.05)。治疗后,两组LVEF、LVEDD、LDL-C、hs-CRP、BNP和6 min步行距离均较治疗前有所改善(P﹤0.05),且瑞舒伐他汀组较辛伐他汀组改善程度更明显(P﹤0.05)。结论瑞舒伐他汀联合常规治疗对CHF疗效优于辛伐他汀联合常规治疗,值得推广。
目的:比較瑞舒伐他汀和辛伐他汀對慢性心力衰竭( CHF)的療效。方法選取CHF患者108例,隨機分為兩組,在常規治療的基礎上,分彆加用辛伐他汀(20 mg/d)和瑞舒伐他汀(20 mg/d)治療,療程為6箇月。在治療前後,檢測患者低密度脂蛋白膽固醇( LDL-C)、高密度脂蛋白膽固醇( HDL-C)、高敏C反應蛋白( hs-CRP)、B型尿鈉肽( BNP)、左室射血分數( LVEF)、左室舒張末內徑( LVEDD),併評估紐約心髒病學會( NYHA)心功能分級,記錄6 min步行距離。結果瑞舒伐他汀組和辛伐他汀組總有效率分彆為90.74%、75.93%,有統計學差異( P﹤0.05)。治療後,兩組LVEF、LVEDD、LDL-C、hs-CRP、BNP和6 min步行距離均較治療前有所改善(P﹤0.05),且瑞舒伐他汀組較辛伐他汀組改善程度更明顯(P﹤0.05)。結論瑞舒伐他汀聯閤常規治療對CHF療效優于辛伐他汀聯閤常規治療,值得推廣。
목적:비교서서벌타정화신벌타정대만성심력쇠갈( CHF)적료효。방법선취CHF환자108례,수궤분위량조,재상규치료적기출상,분별가용신벌타정(20 mg/d)화서서벌타정(20 mg/d)치료,료정위6개월。재치료전후,검측환자저밀도지단백담고순( LDL-C)、고밀도지단백담고순( HDL-C)、고민C반응단백( hs-CRP)、B형뇨납태( BNP)、좌실사혈분수( LVEF)、좌실서장말내경( LVEDD),병평고뉴약심장병학회( NYHA)심공능분급,기록6 min보행거리。결과서서벌타정조화신벌타정조총유효솔분별위90.74%、75.93%,유통계학차이( P﹤0.05)。치료후,량조LVEF、LVEDD、LDL-C、hs-CRP、BNP화6 min보행거리균교치료전유소개선(P﹤0.05),차서서벌타정조교신벌타정조개선정도경명현(P﹤0.05)。결론서서벌타정연합상규치료대CHF료효우우신벌타정연합상규치료,치득추엄。
Objective To compare the curative effects of rosuvastatin and simvastatin on chronic heart failure( CHF ). Methods 108 patients of CHF were randomly divided into 2 groups:rosuvastatin group and simvastatin group. The routine treatment was applied to both groups,while simvastatin,20 mg/d,was added to patients in simvastatin group and rosuvastatin,20 mg/d,to patients in rosuvastatin group;the total course lasted for 6 months. Before and after treatment,detections of LDL-C,HDL-C,hs-CRP,BNP,LVEF and LVEDD were performed as well as the evaluation of cardiac function according to New York Heart Association( NYHA ) classification and the distance of 6-minute walk test(6MWT). Results The total effective rate was 90. 74% in rosuvastatin group and 75.93% in simvastatin group,the difference was of statistical significance(P ﹤0. 05);improvement in LVEF,LVEDD,LDL-C,hs-CRP,BNP and 6MWT was found in both groups after treatment(P﹤0. 05)and the improvement in rosuvastatin group was greater than that in simvastatin group(P﹤0. 05). Conclusions The effect of rosuvastatin combined with routine treatment is much superior to that of simvastatin on CHF,and a wider clinical application should be promoted.